country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-149076

Copy Link Print Information

hGAPDH-IN-1

hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3044004-63-6
Formel: C₁₂H₁₂BrNO
Molecular Weight:266.13

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

hGAPDH-IN-1 Chemical Structure

CAS. Nr.: 3044004-63-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.

Cellular Effect

Cell Line	Type	Value	Description	References
MIA PaCa-2	IC₅₀	15.2 μM Compound: 11	Antiproliferative activity in human MIA PaCa-2 cells measured after 48 hrs by Crystal violet staining based analysis Antiproliferative activity in human MIA PaCa-2 cells measured after 48 hrs by Crystal violet staining based analysis	[PMID: 37058971]
PANC-1	IC₅₀	21.72 μM Compound: 11	Antiproliferative activity in human PANC-1 cells measured after 48 hrs by Crystal violet staining based analysis Antiproliferative activity in human PANC-1 cells measured after 48 hrs by Crystal violet staining based analysis	[PMID: 37058971]

In Vitro

hGAPDH-IN-1 (compound 11; 1-100 μM; 48 hours) turns out to strongly reduce cancer cell growth in all tested cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

PaCa-3, PaCa-44, PANC-1, and MIA PaCa-2 cell lines
Concentration:

1, 2.5, 5, 10, 25, 50, 100 μM
Incubation Time:

48 hours
Result:

Turned out to strongly reduce cancer cell growth in all tested cell lines.
Had IC₅₀s of 4.69 μM, 16.16 μM, 21.72 μM, 15.2 μM for PaCa-3, PaCa-44, PANC-1, and MIA PaCa-2 cell lines, respectively.

Chemical Information

CAS. Nr. 3044004-63-6
Molecular Weight 266.13
Formel C₁₂H₁₂BrNO
SMILES

BrC1=NOC2(C1)CCCC3=C2C=CC=C3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Andrea Galbiati, et al. Discovery of a spirocyclic 3-bromo-4,5-dihydroisoxazole covalent inhibitor of hGAPDH with antiproliferative activity against pancreatic cancer cells. Eur J Med Chem. 2023 Apr 6;254:115286. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen